Watch Out AstraZeneca PLC (AZN) and Sanofi (SNY), Pfizer (PFE) Makes a Move on Bay Area's Medivation (MDVN)
Biogen (BIIB) Spinning Off Hemophilia Business to Focus On Neurological Disorders
Amid Hemophilia Spinoff, Biogen (BIIB)’s Head of Strategy Returns to Bain Capital
Theranos Allegedly Sent Team of Five Lawyers to Wall Street Journal to Squash Story
IMS Health, Quintiles (Q) to Merge to Form $23 Billion Power House
Delaware Employees Nervous Over AstraZeneca PLC (AZN)'s $1 Billion Cost-Cutting Plans
3 Stocks with Moonshot Potential that are Safer Buys than bluebird bio (BLUE)
Why a Medivation (MDVN) Takeover Just Got a Little Tougher for Potential Suitors Like AstraZeneca PLC (AZN), Pfizer (PFE) and Sanofi (SNY)
Backed by Celgene (CELG) and Novartis AG (NVS), IDEAYA Biosciences Raises $46 Million and Recruits an Arsenal Full of Industry Vets
London Biotech Orchard Therapeutics Launches with $30 Million and Academic Partnerships for Gene Therapy Development
MVM Life Science Partners Closes $233 Million Healthcare Fund
Marina Biotech (MRNA) Acquires Late-Stage Program from Turing in $95 Million Deal
Ionis Pharma (IONS), Kastle Forge $95 Million KYNAMRO Deal
Eli Lilly (LLY) Warns of Job Cuts at Irish Plant
Dynavax (DVAX)'s Possible Hep B Win Could Prove a Threat to GlaxoSmithKline (GSK)
Why Sarepta (SRPT) Didn't Start a Big DMD Trial Quicker
Claims Against Johnson & Johnson (JNJ)'s Talcum Powder Gets Alarming
Novartis AG (NVS)'s Chief Ethics and Compliance Officer Retires
See All News >
Federal Judge Reopens Gilead (GILD) Case Amid Allegations Former Merck & Co. (MRK) Scientist Lied
Cambridge's BIND Therapeutics (BIND) Files for Chapter 11 and Reviews Strategic Alternatives
Startup Homology Medicines Launches With $43 Million Series A, To Be Led By Three Former Shire (SHPG) Execs
FDA Clears Acadia (ACAD)'s NUPLAZID, the First Drug for Psychosis Linked to Parkinson's
AstraZeneca PLC (AZN) to Cut Jobs in $1.5 Billion Cost-Cutting Move, Will Double Down on Cancer
EMD Serono Expansion to Create 150 New Jobs in Massachusetts
Regeneron (REGN)'s Pain Drug Fasinumab Meets Goals in Late Stage Study
Bay Area's GrayBug Bags $44.5 Million Series B
Pfizer (PFE) Rumored to be Selling Its Hospira Pumps Division, With Smiths Group, Fresenius SE and Pamplona Capital Bidding
North Carolina's NephroGenex (NRX) Files for Chapter 11 and Seeks Sale
Valeant (VRX) Seeks Fresh Start with Board Shakeup
BioViva CEO Claims Firm's Age-Reversing Gene Therapy Cut Her Biological Age By 20 Years
VerteCore Will Hire 1,000 Employees to Sell Its New $599 Mobile Spinal Decompression Device
Some Hairstyles May Increase Hair Loss Risk And Make You Go Bald, Johns Hopkins University School of Medicine Study
Why Microsoft Is Buying 10 Million Strands Of DNA
Federal Health Regulators Release Lightly Redacted Theranos Report with More Details
Sienna Biopharma Launches with $34 Million and a Roster Full of Former Kythera (KYTH) Execs
Abbott (ABT) Tries to Back Out of $5.8B Alere (ALR) Deal, But Alere Says It’s Still On
See All News >